Intestine Bacteria and Breast Cancer Risk
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 50 - 69 |
| Updated: | 2/10/2019 |
| Start Date: | August 10, 2011 |
BRANCH:Fecal Microbiota Among Participants in a Pre-paid Health Plan
Background:
- Some bacteria found in the large and small intestines help keep people healthy and aid
digestion. They may also affect a person s risk of developing cancer. Researchers want to
study the relationship between intestinal bacteria and breast cancer risk factors. They can
do this by looking at stool and urine samples from postmenopausal women.
Objectives:
- To study intestinal bacteria and its relationship to urine-based markers of breast cancer
risk in women.
Eligibility:
- Women between 55 and 69 years of age with a recent mammogram that showed no signs of
cancer.
Design:
- Participants will be screened with a medical history and basic health questionnaire.
- At home, participants will complete questionnaires about cancer risk factors and food
consumption.
- Participants will also collect urine and stool samples. They will send the samples to
the designated labs for study.
- No treatment will be provided as part of this protocol.
- Some bacteria found in the large and small intestines help keep people healthy and aid
digestion. They may also affect a person s risk of developing cancer. Researchers want to
study the relationship between intestinal bacteria and breast cancer risk factors. They can
do this by looking at stool and urine samples from postmenopausal women.
Objectives:
- To study intestinal bacteria and its relationship to urine-based markers of breast cancer
risk in women.
Eligibility:
- Women between 55 and 69 years of age with a recent mammogram that showed no signs of
cancer.
Design:
- Participants will be screened with a medical history and basic health questionnaire.
- At home, participants will complete questionnaires about cancer risk factors and food
consumption.
- Participants will also collect urine and stool samples. They will send the samples to
the designated labs for study.
- No treatment will be provided as part of this protocol.
Background/Significance: Commensal microbes (the microbiota), particularly in the gut, are
required for human health and are postulated to affect cancer risk through several
mechanisms. This proposed study builds upon a pilot within the NCI Division of Cancer
Epidemiology and Genetics (DCEG) that identified highly acceptable methods for collecting
fecal specimens and significant correlation between fecal microbial beta-glucuronidase
activity and a marker of breast cancer risk, urine levels of estrogens. The proposed study
will determine the correlation between levels of fecal enzyme activities and systemic
estrogens in a random sample of postmenopausal women at Kaiser Permanente Colorado (KPCO).
Demonstration of an association between the fecal microbiota and systemic estrogens would
help to motivate future studies of how microbes affect cancer risk.
Objectives: The main objective is to characterize the fecal microbiota and its association
with levels of systemic estrogens among randomly sampled postmenopausal female members of a
health maintenance organization (HMO). A secondary objective will determine the proportions
of women who consent and then provide questionnaire data, a fecal specimen to characterize
the microbiota, and a urine specimen to quantify systemic estrogens; and differences between
participants (N=60) and non-participants. A third objective will determine whether
consecutive, newly diagnosed postmenopausal breast cancer cases have similar participation
rates, fecal microbiota characteristics and urine estrogen levels compared to the randomly
sampled women.
Methods: We will randomly sample from the KPCO population of approximately 50,000 women ages
55-69 who have recently had a negative screening mammogram. An invitation packet (letter,
information pamphlet, consent form, eligibility questionnaire, and opt-out postcard) will be
sent in batches of 100, up to a maximum of 500 women. The consenting women will receive a
second packet with a cancer risk-factor questionnaire, a link to the on-line Block brief food
frequency questionnaire, and a specimen collection kit (with illustrated instructions) for
collecting a fecal and urine specimen. Participants (minimum 60, maximum 80) will ship the
specimens to the DCEG repository. As amended, consecutive newly diagnosed breast cancer cases
(target N=60) will be enrolled in the oncology clinic prior to definitive surgery, with the
same eligibility criteria as for the random sample. For contemporaneous controls,
participants in the randomly sampled, mammogram-negative population will be recruited back
(target N=60). Urine estrogens will be quantified by DCEG at NCI Frederick. Fecal microbial
classification and enzymatic expression and activity will be performed at the University of
Maryland Medical School (UMMS).
Analyses: Data will be analyzed and summarized for publication with representatives from
KPCO, DCEG and UMMS. Simple proportions will be used to estimate participation rates. Extant
electronic records at KPCO will be used to compare participants to non-participants, overall
and by pre-specified subgroups (5-year age groups, race/ethnicity, length of KPCO
enrollment), with descriptive statistics and logistic regression. For the primary objective,
fecal microbial 16S rRNA pyrosequences will be classified by phylogenetic and principal
components analyses, while estrogen levels and Beta-glucuronidase RNA expression and
enzymatic activity levels will be categorized using log standard deviations. The study will
have 80% power to detect a 17% increase in estrogen level per 2.4-fold increase in
glucuronidase activity and 80% power to detect a 3-fold case-control difference in
above-median microbiome alpha diversity.
required for human health and are postulated to affect cancer risk through several
mechanisms. This proposed study builds upon a pilot within the NCI Division of Cancer
Epidemiology and Genetics (DCEG) that identified highly acceptable methods for collecting
fecal specimens and significant correlation between fecal microbial beta-glucuronidase
activity and a marker of breast cancer risk, urine levels of estrogens. The proposed study
will determine the correlation between levels of fecal enzyme activities and systemic
estrogens in a random sample of postmenopausal women at Kaiser Permanente Colorado (KPCO).
Demonstration of an association between the fecal microbiota and systemic estrogens would
help to motivate future studies of how microbes affect cancer risk.
Objectives: The main objective is to characterize the fecal microbiota and its association
with levels of systemic estrogens among randomly sampled postmenopausal female members of a
health maintenance organization (HMO). A secondary objective will determine the proportions
of women who consent and then provide questionnaire data, a fecal specimen to characterize
the microbiota, and a urine specimen to quantify systemic estrogens; and differences between
participants (N=60) and non-participants. A third objective will determine whether
consecutive, newly diagnosed postmenopausal breast cancer cases have similar participation
rates, fecal microbiota characteristics and urine estrogen levels compared to the randomly
sampled women.
Methods: We will randomly sample from the KPCO population of approximately 50,000 women ages
55-69 who have recently had a negative screening mammogram. An invitation packet (letter,
information pamphlet, consent form, eligibility questionnaire, and opt-out postcard) will be
sent in batches of 100, up to a maximum of 500 women. The consenting women will receive a
second packet with a cancer risk-factor questionnaire, a link to the on-line Block brief food
frequency questionnaire, and a specimen collection kit (with illustrated instructions) for
collecting a fecal and urine specimen. Participants (minimum 60, maximum 80) will ship the
specimens to the DCEG repository. As amended, consecutive newly diagnosed breast cancer cases
(target N=60) will be enrolled in the oncology clinic prior to definitive surgery, with the
same eligibility criteria as for the random sample. For contemporaneous controls,
participants in the randomly sampled, mammogram-negative population will be recruited back
(target N=60). Urine estrogens will be quantified by DCEG at NCI Frederick. Fecal microbial
classification and enzymatic expression and activity will be performed at the University of
Maryland Medical School (UMMS).
Analyses: Data will be analyzed and summarized for publication with representatives from
KPCO, DCEG and UMMS. Simple proportions will be used to estimate participation rates. Extant
electronic records at KPCO will be used to compare participants to non-participants, overall
and by pre-specified subgroups (5-year age groups, race/ethnicity, length of KPCO
enrollment), with descriptive statistics and logistic regression. For the primary objective,
fecal microbial 16S rRNA pyrosequences will be classified by phylogenetic and principal
components analyses, while estrogen levels and Beta-glucuronidase RNA expression and
enzymatic activity levels will be categorized using log standard deviations. The study will
have 80% power to detect a 17% increase in estrogen level per 2.4-fold increase in
glucuronidase activity and 80% power to detect a 3-fold case-control difference in
above-median microbiome alpha diversity.
- INCLUSION CRITERIA:
Female members of Kaiser Permanente Colorado (KPCO) with a recent normal mammogram who gets
into a random sample of the very large population.
EXCLUSION CRITERIA:
History of cancer, except non-melanoma skin cancer
History of inflammatory bowel disease or diverticulitis
History of gastric banding or by-pass surgery
History of other gastric or intestinal surgery within the previous 6 months
Hormone prescription within the previous 12 months
Antibiotic prescription within the previous 6 months.
We found this trial at
1
site
Click here to add this to my saved trials
